Progenics Pharmaceuticals, Inc. (PGNX) Forms $5.84 Double Bottom; Daruma Capital Management Has Trimmed Wex (WEX) Position By $1.16 Million

Progenics Pharmaceuticals, Inc. (PGNX) formed double bottom with $5.61 target or 4.00% below today’s $5.84 share price. Progenics Pharmaceuticals, Inc. (PGNX) has $410.38 million valuation. The stock increased 2.10% or $0.12 during the last trading session, reaching $5.84. About 156,848 shares traded. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has risen 48.41% since February 15, 2017 and is uptrending. It has outperformed by 31.71% the S&P500.

Daruma Capital Management Llc decreased Wex Inc (WEX) stake by 2.2% reported in 2017Q3 SEC filing. Daruma Capital Management Llc sold 10,329 shares as Wex Inc (WEX)’s stock declined 10.14%. The Daruma Capital Management Llc holds 459,160 shares with $51.53 million value, down from 469,489 last quarter. Wex Inc now has $6.10 billion valuation. The stock decreased 0.14% or $0.2 during the last trading session, reaching $142.06. About 30,795 shares traded. WEX Inc. (NYSE:WEX) has risen 13.96% since February 15, 2017 and is uptrending. It has underperformed by 2.74% the S&P500.

Among 5 analysts covering Progenics Pharm (NASDAQ:PGNX), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Progenics Pharm had 11 analyst reports since August 6, 2015 according to SRatingsIntel. The rating was maintained by Jefferies on Tuesday, September 26 with “Buy”. Brean Capital maintained Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) rating on Thursday, August 6. Brean Capital has “Buy” rating and $14 target. The rating was maintained by Needham with “Buy” on Tuesday, June 20. On Thursday, June 8 the stock rating was maintained by Jefferies with “Buy”. Aegis Capital initiated the shares of PGNX in report on Thursday, October 27 with “Buy” rating. Zacks downgraded the shares of PGNX in report on Friday, August 7 to “Buy” rating. The firm has “Strong Buy” rating by Needham given on Monday, February 6. The stock of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) earned “Buy” rating by Needham on Friday, August 7. The rating was upgraded by Jefferies on Friday, October 23 to “Buy”. The rating was maintained by Cantor Fitzgerald on Wednesday, August 9 with “Buy”.

Investors sentiment decreased to 1.11 in 2017 Q3. Its down 0.18, from 1.29 in 2017Q2. It worsened, as 22 investors sold Progenics Pharmaceuticals, Inc. shares while 34 reduced holdings. 16 funds opened positions while 46 raised stakes. 58.90 million shares or 4.84% less from 61.90 million shares in 2017Q2 were reported. Sector Pension Board has 0% invested in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Thrivent For Lutherans reported 0% of its portfolio in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Moreover, Principal Group Inc Inc has 0% invested in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Ls Invest Advsr Limited Liability holds 0.01% or 22,806 shares. Citigroup holds 155,203 shares or 0% of its portfolio. Alliancebernstein Limited Partnership holds 0% of its portfolio in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) for 94,652 shares. Manufacturers Life Com The owns 61,054 shares for 0% of their portfolio. Assetmark invested in 0% or 200 shares. Fifth Third Financial Bank reported 0% of its portfolio in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Clarivest Asset Mgmt Limited Liability stated it has 186,174 shares or 0.03% of all its holdings. Stifel Fin stated it has 25,563 shares. Moreover, Ubs Asset Americas has 0% invested in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Susquehanna Intll Grp Llp owns 0% invested in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) for 122,379 shares. Blair William And Il has invested 0% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Raymond James Assocs holds 53,378 shares or 0% of its portfolio.

Analysts await Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) to report earnings on March, 8. They expect $-0.21 earnings per share, down 110.00% or $0.11 from last year’s $-0.1 per share. After $-0.22 actual earnings per share reported by Progenics Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -4.55% EPS growth.

Investors sentiment increased to 2.02 in 2017 Q3. Its up 0.53, from 1.49 in 2017Q2. It increased, as 21 investors sold WEX shares while 40 reduced holdings. 24 funds opened positions while 99 raised stakes. 46.62 million shares or 2.64% more from 45.42 million shares in 2017Q2 were reported. Eaton Vance Mgmt has 0% invested in WEX Inc. (NYSE:WEX). 1,786 were reported by Jane Street Limited Company. D E Shaw & holds 0.01% of its portfolio in WEX Inc. (NYSE:WEX) for 54,822 shares. Automobile Association reported 167,382 shares. Natixis accumulated 4,899 shares. California Pub Employees Retirement Sys accumulated 62,871 shares. Employees Retirement Systems Of Ohio reported 0.04% stake. Moreover, Renaissance Techs Lc has 0.01% invested in WEX Inc. (NYSE:WEX) for 65,300 shares. New York-based Junto Cap Mngmt Lp has invested 2.81% in WEX Inc. (NYSE:WEX). Federated Pa holds 0.01% or 15,566 shares in its portfolio. Retirement Of Alabama invested in 0.03% or 51,483 shares. Teachers Retirement System Of The State Of Kentucky invested 0.09% of its portfolio in WEX Inc. (NYSE:WEX). Bancorp Of Montreal Can reported 0.01% in WEX Inc. (NYSE:WEX). Point72 Asia (Hong Kong) reported 0.01% stake. Manufacturers Life Insurance The invested 0.01% of its portfolio in WEX Inc. (NYSE:WEX).